Discover and read the best of Twitter Threads about #CardioOncology
Most recents (6)
We finish this week of Core Curriculum with a remarkable lecture on cardio-oncology from Dr. Gagan Sahni 
🔑take home points
1) Cancer Therapeutic Related Cardiac Dysfunction (CTRCD) defined as decrease in ❤️LVEF >10% from baseline to a value <55%
2) Type 1 cardiotoxicity such as from Anthracyclines 💉is dose related, cumulative, and irreversible and Dexrazoxane can reduce risk
1) Cancer Therapeutic Related Cardiac Dysfunction (CTRCD) defined as decrease in ❤️LVEF >10% from baseline to a value <55%
2) Type 1 cardiotoxicity such as from Anthracyclines 💉is dose related, cumulative, and irreversible and Dexrazoxane can reduce risk
3) Type 2 cardiotoxicity such as from trastuzumab leads to reversible cardiac dysfunction, is reversible, but is not dose related
4) GDMT💊can allow for continued dosing of trastuzumab in those with asymptomatic cardiac dysfunction
4) GDMT💊can allow for continued dosing of trastuzumab in those with asymptomatic cardiac dysfunction
Pulmonary Hypertension 🫁
Ventricular Arrhythmias⚡️
1. Today is #WorldCancerDay our analysis led by @dr_mosama & @hvanspall academic.oup.com/ehjacc/advance… with @AnaBaracCardio @islamelgendy83 @DLBHATTMD @adnanalkhouli @safinmc @dataevan studies disparities in care & outcomes of cancer pts presenting with STEMI @DrMarthaGulati @ShrillaB
2. #WorldCancerDay It builds on our work published last year led by @adityadoc1 showing pts with cancer less likely to be managed invasively, and when they are have better outcomes. academic.oup.com/eurheartj/arti… @MKIttlesonMD @ovidiogarciav @DrPeterOKane @SukhNijjer @CardioIAN
3. #WorldCancerDay The greatest incidence of AMI in cancer pts is within 30d of Ca diagnosis, many treatments can ⬆️risk aswell as shared risk factors. We sought to study whether STEMI pts with cancer are less likley to get PPCI & whether they benefit academic.oup.com/ehjacc/advance…
1/ Hot-off-the-press 🔥✍🏽🗣
Precision #CardioOncology: Systems-based Perspective on Tyrosine Kinase Inhibitors & Immune Checkpoint Inhibitors
#PrecisionCardioOnc @SpringerNature
Latest manuscript w/ @MayoClinicCV @mayocvonc & edited by @AnaBaracCardio
rdcu.be/b3q0Y
Precision #CardioOncology: Systems-based Perspective on Tyrosine Kinase Inhibitors & Immune Checkpoint Inhibitors
#PrecisionCardioOnc @SpringerNature
Latest manuscript w/ @MayoClinicCV @mayocvonc & edited by @AnaBaracCardio
rdcu.be/b3q0Y
2/ 🔥✍🏽🗣
A broad spectrum of #CVD toxicities can be seen with targeted therapies or #ICIs
Toxicities of one or the other can include cardiomyopathy, HF, myocarditis, venous or arterial thrombosis, progression of atherosclerosis, QTc prolongation, or arrhythmias
#CardioOnc
A broad spectrum of #CVD toxicities can be seen with targeted therapies or #ICIs
Toxicities of one or the other can include cardiomyopathy, HF, myocarditis, venous or arterial thrombosis, progression of atherosclerosis, QTc prolongation, or arrhythmias
#CardioOnc
3/ 🔥✍🏽🗣
An eminent need is optimal risk management, surveillance, detection, and prevention
The heterogeneities of patient populations, risks, and disease spectra have complicated clinical and translation efforts
#cvPrev #PrevCardioOnc #CardioOnc
An eminent need is optimal risk management, surveillance, detection, and prevention
The heterogeneities of patient populations, risks, and disease spectra have complicated clinical and translation efforts
#cvPrev #PrevCardioOnc #CardioOnc
1/ Hot-off-the-press!
Tweetorial on Role of Angiotensin‐Converting Enzyme Inhibitors & β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Pts
ahajournals.org/doi/10.1161/JA…
#CardioOnc #CardioOncology #PrevCardioOnc
@avolgman @AnaBaracCardio @DrTochiCardiOnc
Tweetorial on Role of Angiotensin‐Converting Enzyme Inhibitors & β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Pts
ahajournals.org/doi/10.1161/JA…
#CardioOnc #CardioOncology #PrevCardioOnc
@avolgman @AnaBaracCardio @DrTochiCardiOnc
2/ Approx 4 million American 👩🏽👩🦳 are currently living with a hx of invasive breast ca, w/ 270,000 diagnosed within the past year. Among these 👩🏽👩🦳, 64% are aged ≥65 years. Among older 👩🏽👩🦳 survivors of breast cancer, cardiovascular disease (#CVD) is the leading cause of death
3/ Are ACEIs and β‐blockers indicated and efficacious for everyone with breast cancer? Should we offer these medications prophylactically to all patients planned for chemotherapy, radiation, or targeted therapy? #CardioOnc #CardioOncology
1/ Preventive Cardio-Oncology Tutorial #PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”
tinyurl.com/PrevCardioOncT…
“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”
tinyurl.com/PrevCardioOncT…
2/ “A myriad of novel cardiotoxic chemotherapeutic & immunotherapeutic drugs are continuously being developed in #Oncology, with diverse cardiovascular (CV) effects.”
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
3/ Chest radiation “can result in accelerated atherosclerosis, pericardial disease, valve disease, conduction abnormalities, & cardiomyopathies.”
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
